工艺研究员/Research Investigator, CMC Drug Substance(博士)当面告知
百濟神州有限公司
2026-12-15 15:28:34
校招博士27届
岗位详情
地区：
北京
专业要求：
材料科学与工程化学工程与工艺
岗位职责：
We are seeking a highly motivated Investigator to join the Solid State Development team within Drug Substance (DS) Development. The successful candidate will support the discovery, characterization, and selection of pharmaceutical solid forms, including polymorphs, salts, co-crystals, hydrates, and solvates, for innovative small-molecule drug candidates. The role will focus on solid form screening, crystallization process development, and solid-state characterization to enable efficient drug substance and drug product development. The position offers opportunities to work in a multidisciplinary CMC environment and contribute to the development of novel medicines from early development through clinical stages.
Education
PhD degree in Pharmaceutical Sciences, Physical Chemistry, Materials Science, Chemical Engineering, Crystallography, or a related discipline.
招聘要求：
We are seeking a highly motivated Investigator to join the Solid State Development team within Drug Substance (DS) Development. The successful candidate will support the discovery, characterization, and selection of pharmaceutical solid forms, including polymorphs, salts, co-crystals, hydrates, and solvates, for innovative small-molecule drug candidates. The role will focus on solid form screening, crystallization process development, and solid-state characterization to enable efficient drug substance and drug product development. The position offers opportunities to work in a multidisciplinary CMC environment and contribute to the development of novel medicines from early development through clinical stages.
Education
PhD degree in Pharmaceutical Sciences, Physical Chemistry, Materials Science, Chemical Engineering, Crystallography, or a related discipline.
公司介绍
百濟神州有限公司
百濟神州有限公司，成立于2018-06-28，位于香港，登记状态：仍注册，注册资本15.4142万美元，公司类型：中外合资
百济神州有限公司是一家商业化阶段的生物技术公司，专注于开发及商业化用于治疗癌症的创新型分子靶向及肿瘤免疫治疗药物。百济神州拥有广泛全面的产品组合。其产品包括六种内部开发、临床阶段的候选药物，其中包括三种后期临床候选药物,zanubrutinib(BTK抑制剂),tislelizumab(PD-1抗体)与pamiparib(PARP抑制剂)。百济神州亦获得五种药物及在研药物的授权许可，包括三种已于中国销售的由新基独家授权的药物ABRAXANE、REVLIMID 及VIDAZA,及两种临床阶段的在研药物，该种药物已获得于中国及亚太地区的其他指定国家开发及商业化的权利。百济神州于2010年于北京成立并在2016年2月在美国纳斯达克全球精选市场上市。截至2018年7月，公司拥有一支超过1300名员工的全球团队，成为一家拥有涵盖研究、临床开发、生产及商业化的全面实力的全球生物技术公司。